Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL

被引：115
|
作者：
Maude, Shannon L.
Teachey, David T.
Rheingold, Susan R.
Shaw, Pamela A.
Aplenc, Richard
Barrett, David Maxwell
Barker, Christine S.
Callahan, Colleen
Frey, Noelle V.
Nazimuddin, Farzana
Lacey, Simon F.
Zheng, Zhaohui
Levine, Bruce
Melenhorst, Jan Joseph
Motley, Laura
Porter, David L.
June, Carl H.
Grupp, Stephan A.
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA USA
[2] Univ Pennsylvania, Philadelphia, PA USA
[3] Univ Pennsylvania, Abramson Canc Ctr, Philadelphia, PA USA
[4] Univ Pennsylvania, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA USA
[5] Univ Pennsylvania, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Chimeric Antigen Receptor (CAR)-Modified T Cells (CTL019) Induce Durable CNS Remissions in Children with CNS/Combined Bone Marrow and CNS Relapsed/Refractory CD19+Acute Lymphoblastic Leukemia
    Talekar, Mala
    Hucks, George
    Maude, Shannon
    Kawchak, Nicholas
    Motley, Laura
    Barrett, David
    Lacey, Simon
    Levine, Bruce
    Melenhorst, Jan
    Shaw, Pamela
    Callahan, Colleen
    White, Claire
    Barker, Christine
    Baniewicz, Diane
    Duckworth, Mark
    Aplenc, Richard
    Teachey, David
    June, Carl
    Grupp, Stephan
    Rheingold, Susan
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S2 - S2
  • [32] CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era
    Hay, Kevin A.
    Turtle, Cameron J.
    IMMUNOTHERAPY, 2018, 10 (04) : 251 - 254
  • [33] Quantitative single-cell functional characterization of CD19-specific chimeric antigen receptor T cells
    Varadarajan, Navin
    Liadi, Ivan
    Romain, Gabrielle
    Singh, Harjeet
    Cooper, Laurence
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [34] On the cause and consequence of intestinal domination of Enterococcus spp. in patients treated with CD19-specific chimeric antigen receptor (CAR) T cells
    Rohrbach, R.
    Blumenberg, V.
    Schubert, M. -L.
    Zamir, E.
    Schmidt, S.
    Hillebrandt, N.
    Bozic, D.
    von Bergwelt, M.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    Subklewe, M.
    Stein-Thoeringer, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 192 - 192
  • [35] Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
    Diaconu, Iulia
    Ballard, Brandon
    Zhang, Ming
    Chen, Yuhui
    West, John
    Dotti, Gianpietro
    Savoldols, Barbara
    MOLECULAR THERAPY, 2017, 25 (03) : 580 - 592
  • [36] Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition
    Turtle, Cameron J.
    Sommermeyer, Daniel
    Berger, Carolina
    Hudecek, Michael
    Shank, David M.
    Steevens, Natalia N.
    Budiarto, Tanya M.
    Karimi, Mandana
    Chaney, Colette N.
    DeVito, Anna Marie
    Heimfeld, Shelly
    Jensen, Michael C.
    Riddell, Stanley R.
    Maloney, David G.
    BLOOD, 2014, 124 (21)
  • [37] Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
    Stock, Sophia
    Uebelhart, Rudolf
    Schubert, Maria-Luisa
    Fan, Fuli
    He, Bailin
    Hoffmann, Jean-Marc
    Wang, Lei
    Wang, Sanmei
    Gong, Wenjie
    Neuber, Brigitte
    Hueckelhoven-Krauss, Angela
    Gern, Ulrike
    Christ, Christiane
    Hexel, Monika
    Schmitt, Anita
    Schmidt, Patrick
    Krauss, Juergen
    Jaeger, Dirk
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    Sellner, Leopold
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1312 - 1324
  • [38] Long-Term Remission of CLL Sustained by Oligoclonal CD19-Specific Chimeric Antigen Receptor T Cell Clones
    Melenhorst, J. Joseph
    Porter, David L.
    Nobles, Christopher L. L.
    Wang, Meng
    Tian, Lifeng
    Lacey, Simon F.
    Aliano, Cecile
    Fraietta, Joseph
    Frey, Noelle V.
    Kulikovskaya, Irina
    Gupta, Minnal
    Young, Regina M.
    Levine, Bruce L.
    Siegel, Donald L.
    Wherry, E. John
    Bushman, Frederic D.
    June, Carl H.
    MOLECULAR THERAPY, 2019, 27 (04) : 169 - 169
  • [39] Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia
    Wang, Shiyuan
    Wang, Xue
    Ye, Chunying
    Cheng, Hai
    Shi, Ming
    Chen, Wei
    Qi, Kunming
    Wang, Gang
    Wu, Qingyun
    Zeng, Lingyu
    Li, Zhenyu
    Jing, Guangjun
    Zheng, Junnian
    Xu, Kailin
    Cao, Jiang
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E162 - E165
  • [40] Artificial antigen presenting cell can be used to propagate genetically modified CD19-specific T cells through chimeric antigen receptor.
    Numbenjapon, T
    Serrano, LMA
    Olivares, S
    Chang, WC
    Singh, H
    Kowolik, CM
    Gonzalez, S
    Gonzalez, N
    Cooper, LJN
    BLOOD, 2005, 106 (11) : 377A - 377A
12345